Early treatment with Ocrevus may help protect the cerebellum from damage in people with multiple sclerosis, a study found.

The upcoming 12th Annual Clinical Trials in Oncology conference will cover a wide range of topics on clinical research in ...

Researchers studied 118 SMA type 2 patients and saw their RULM scores stayed higher than expected had their disease kept its ...

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker ...

Holdings will be presenting a poster at the American Society of Clinical Oncology 2025 Annual Meeting to be held May ...

Treatment with regulatory T-cells, known as Tregs, was well tolerated and seemed to reduce disease activity in a small ...

Affiliate links for the products on this page are from partners that compensate us and terms apply to offers listed (see our advertiser disclosure with our list of partners for more details ...

ICON Public Limited Company’s ICLR share price has surged by 5.63%, which has investors questioning if this is right time to sell.

Here, the authors report a phase 2 clinical trial investigating immune activation and efficacy of neoadjuvant pembrolizumab administered after one cycle of neo-adjuvant chemotherapy in patients ...

Don’t waste another minute; get started by clicking here here.(Sponsor) ICON (NASDAQ:ICLR) is a research company that specializes in clinical trials. It is a profitable company that has been on a ...

The first ALS patient has been enrolled in an NIH-funded expanded access program trial evaluating MN-166 (ibudilast).

April 15, 2025—enVVeno Medical Corporation recently announced the presentation of findings from a subanalysis of the 1-year data from the prospe ...